search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Neurosis.


- candidate number14489
- NTR NumberNTR3891
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR11-mrt-2013
- Secondary IDsNL35679.078.11 CCMO
- Public TitleNeurosis.
- Scientific TitleEfficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia.
- ACRONYM
- hypothesisThe hypothesis of this study is that early prophylactic inhalation of budesonide reduces the absolute risk of BPD or death in preterm infants born <28 weeks gestational age by 10%.
- Healt Condition(s) or Problem(s) studiedPremature infants, Inhaled corticosteroids, Bronchopulmonary dysplasia
- Inclusion criteria1. Gestational age of 23 0/7-27 6/7 weeks;
2. Postnatal age < 12 hours;
3. Necessity for any form of positive pressure support (mechanical or nasal ventilation or CPAP);
4. Singleton or second born in case of multiple pregnancy;
5. Parental consent for participation.
- Exclusion criteriaA clinical decision not to administer therapies (infant not considered viable), dysmorphic features or congenital malformations that adversely affect life expectancy or neurodevelopment and known or suspected congenital heart disease (not including a persistent ductus arteriosus and/or an atrial septum defect). The clinical assessment of dysmorphic features, congenital malformations, suspected congenital heart disease and the decision to exlude an infant for the afore mentioned reasons will be left to the discretion of the attending physician.
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 15-mrt-2013
- planned closingdate31-dec-2013
- Target number of participants20
- InterventionsWithin 2 years 850 infants of 23-27 weeks GA will be randomised during the first 12 hours of life to Budesonide (BS) or placebo to prevent BPD. Study drugs will be administered via Aerochamber and continued until infants are either off supplementary oxygen and poitive pressure support of have reached a GA of 32 O/7 weeks regardless of ventilatory status.
- Primary outcomeThe primary outcome is defined as a combination of BPD or death at 36 weeks gestational age.
- Secondary outcome1. Neurodevelopmental outcomes at 18 - 22 months;
2. Adverse treatment effects;
3. Mortality at 36 weeks gestationale age;
4. BPD incidence at 36 weeks gestational age;
5. Duration of positive pressure respiratory support or supplemental oxygen.
- Timepoints1. 36 weeks gestational age;
2. 22 months.
- Trial web siteN/A
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIESDr. R.K. Kornelisse
- CONTACT for SCIENTIFIC QUERIESDr. R.K. Kornelisse
- Sponsor/Initiator Neurosis study Center
- Funding
(Source(s) of Monetary or Material Support)
Neurosis Study Center Tuebingen
- PublicationsN/A
- Brief summaryBackground of the study:
https://toetsingonline.ccmo.nl/icons/ecblank.gif
Survival of extremely low birth weight (ELBW) infants has improved in recent decades, however BPD remains a major health care problem. BPD is a chronic lung disease that occurs in premature infants. BPD not only contributes to the mortality of preterm infants but is also associated with impaired psychomotor outcome in ELBW survivors. A number of approaches followed in preventing or treating BPD have been evaluated in the context of controlled studies. Among the interventions studied are antenatal and postnatal corticosteroids Systemic postnatal corticosteroid treatment is perhaps the most controversial approach known in BPD care. Several reports on the adverse effects of dexamethasone on growth and neurodevelopmental outcomes appeared, thus the widespread use of systemic postnatal steroids was replaced by almost complete avoidance of this form of therapy. Nevertheless, the incidence of ELBW survivors with BPD is increasing and new modalities for prevention and treatment need to be explored. Inhaled corticosteroids have been established as the first-line of treatment in adults and children with persistent asthma, the most common chronic inflammatory disease. As in asthma, the biological rationale of corticosteroid therapy in infants with evolving or established BPD is based on its anti-inflammatory properties. Some trials concerning inhaled corticosteroids did not prevent BPD, but was associated with a lower use of systemic glucocorticoid therapy and mechanical ventilation. One study with Inhaled steroids resulted in a significantly higher success rate in extubation within the first 2 weeks of life and a more pronounced improvement in lung compliance. A study to evaluate the efficacy of inhaled corticosteroids seems to be justified. The hypothesis of this study is that early prophylactic inhalation of budesonide reduces the absolute risk of BPD or death in preterm infants born <28 weeks gestational age by 10%.

Objective of the study:
https://toetsingonline.ccmo.nl/icons/ecblank.gif
Primary objective - Survival without BPD at 36 weeks gestational age (GA) Secondary objectives - Neurodevelopment at a corrected age of 18-22 months - Adverse treatment effects - Mortality at 36 weeks gestational age - BPD incidence at 36 weeks gestational age - Duration of positive pressure respiratory support or supplemental oxygen.

Study design:
https://toetsingonline.ccmo.nl/icons/ecblank.gif
Randomised placebo-controlled, multicentre clinical trial.

Study population:
https://toetsingonline.ccmo.nl/icons/ecblank.gif
Preterm infants born between 23 0/7 and 27 6/7 weeks gestational age (GA).

Intervention:
https://toetsingonline.ccmo.nl/icons/ecblank.gif
Within 2 years 850 infants of 23-27 weeks GA will be randomised during the first 12 hours of life to Budesonide (BS) of placebo to prevent BPD. Study drugs will be administered via Aerochamber and continued until infants are either off supplementary oxygen and poitive pressure support of have reached a GA of 32 O/7 weeks regardless of ventilatory status.

Primary study parameters/outcome of the study:
https://toetsingonline.ccmo.nl/icons/ecblank.gif
The primary outcome is defined as a combination of BPD or death at 36 weeks gestational age.

Secundary study parameters/outcome of the study:
https://toetsingonline.ccmo.nl/icons/ecblank.gif
- Neurodevelopmental outcomes at 18 - 22 months; - Adverse treatment effects; - Mortality at 36 weeks gestationale age; - BPD incidence at 36 weeks gestational age; - Duration of positive pressure respiratory support or supplemental oxygen.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
https://toetsingonline.ccmo.nl/icons/ecblank.gif
Inflammation is central to the development of BPD. Corticosteroids (CS) have antiinflammatory properties and early inhalation of CS may allow for beneficial local effects on the pulmonary system with a lower risk of undesirable systemic side effects.
- Main changes (audit trail)
- RECORD11-mrt-2013 - 26-apr-2013


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl